{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:48:12Z","timestamp":1791776892697,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR 219"],"award-info":[{"award-number":["SFB TRR 219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017005","name":"Deutsche Hochdruckliga","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bcp.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T11:11:27Z","timestamp":1562325087000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling"],"prefix":"10.1016","volume":"168","author":[{"given":"Daniel","family":"Lavall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2019.07.001_b0005","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2013a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2019.07.001_b0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac Fibrosis: The Fibroblast Awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.bcp.2019.07.001_b0015","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1161\/HYPERTENSIONAHA.106.077537","article-title":"Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis","volume":"49","author":"Koitabashi","year":"2007","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.bcp.2019.07.001_b0020","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MNH.0b013e3282f56854","article-title":"Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation","volume":"17","author":"Young","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bcp.2019.07.001_b0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"issue":"18","key":"10.1016\/j.bcp.2019.07.001_b0035","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1074\/jbc.M116.764449","article-title":"Rac1 GTPase regulates 11beta hydroxysteroid dehydrogenase type 2 and fibrotic remodeling","volume":"292","author":"Lavall","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2019.07.001_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis","volume":"188","author":"Vukadinovic","year":"2017","journal-title":"Am. Heart J."},{"issue":"8","key":"10.1016\/j.bcp.2019.07.001_b0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"27","key":"10.1016\/j.bcp.2019.07.001_b0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bcp.2019.07.001_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.06054","article-title":"Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury","volume":"67","author":"Ayuzawa","year":"2016","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0065","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jacc.2007.03.041","article-title":"Role of Rac1 GTPase activation in atrial fibrillation","volume":"50","author":"Adam","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2019.07.001_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jacc.2009.08.064","article-title":"Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation","volume":"55","author":"Adam","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.yjmcc.2010.12.019","article-title":"Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation","volume":"50","author":"Adam","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2019.07.001_b0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00395-012-0278-0","article-title":"Role of miR-21 in the pathogenesis of atrial fibrosis","volume":"107","author":"Adam","year":"2012","journal-title":"Bas. Res. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2019.07.001_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0095","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0008-6363(01)00540-5","article-title":"Impact of HMG CoA reductase inhibition on small GTPases in the heart","volume":"53","author":"Laufs","year":"2002","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.bcp.2019.07.001_b0100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1172\/JCI8497","article-title":"Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1","volume":"105","author":"Sussman","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2019.07.001_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cardiores.2006.04.005","article-title":"Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy","volume":"71","author":"Custodis","year":"2006","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.steroids.2008.10.010","article-title":"Mineralocorticoid receptors: emerging complexity and functional diversity","volume":"74","author":"Odermatt","year":"2009","journal-title":"Steroids"},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0120","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-beta signaling in cardiac remodeling","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7224","key":"10.1016\/j.bcp.2019.07.001_b0125","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"issue":"Pt 20","key":"10.1016\/j.bcp.2019.07.001_b0130","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1242\/jcs.00059","article-title":"Fibronectin at a glance","volume":"115","author":"Pankov","year":"2002","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","article-title":"Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview","volume":"350","author":"Odermatt","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.bcp.2019.07.001_b0140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/01.HYP.0000128621.68160.dd","article-title":"Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy","volume":"43","author":"Matsui","year":"2004","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.bcp.2019.07.001_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvt100","article-title":"Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?","volume":"99","author":"Lopez","year":"2013","journal-title":"Cardiovasc. Res."},{"issue":"30","key":"10.1016\/j.bcp.2019.07.001_b0150","doi-asserted-by":"crossref","first-page":"28484","DOI":"10.1074\/jbc.M100374200","article-title":"The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2","volume":"276","author":"Odermatt","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.07.001_b0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.yjmcc.2015.05.019","article-title":"Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice","volume":"85","author":"Adam","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"9","key":"10.1016\/j.bcp.2019.07.001_b0160","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1210\/en.2008-1493","article-title":"Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart","volume":"150","author":"Klusonova","year":"2009","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.bcp.2019.07.001_b0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lombes","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2019.07.001_b0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2019.07.001_b0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2019.07.001_b0185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2019.07.001_b0190","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.bcp.2019.07.001_b0195","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/CIRCULATIONAHA.105.538108","article-title":"Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases","volume":"112","author":"Dudley","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bcp.2019.07.001_b0200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","article-title":"B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation","volume":"94","author":"Kapoun","year":"2004","journal-title":"Circ. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:06:49Z","timestamp":1757768809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":40,"alternative-id":["S0006295219302564"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.07.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}